BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

S hares of global vaccine makers were muted on Tuesday as investors and analysts took a "wait and watch" approach after U.S.

Merck won FDA approval for a shot that protects against RSV, the most common cause of hospitalization among infants ...

As Head of R&D and a member of the Executive Leadership Team, the Company's research, development and medical affairs ...

Merck’s Enflonsia will go up against Sanofi and AstraZeneca’s Beyfortus, which the partners plan to ship out early in the ...

The green light in the US is the first worldwide for Enflonsia ( clesrovimab) and makes the long-acting antibody the first ...

Merck (MRK) stock is in focus as its Enflonsia RSV shot is cleared for infants in the U.S. in a market led by Sanofi (SNY) ...

Investing.com -- Shares of Swedish Orphan Biovitrum (STO:SOBI) fell by 4% today after the FDA approved Merck (NSE: PROR )’s respiratory syncytial virus (RSV) vaccine Enflonsia (clesrovimab), which ...

Sanofi accelerates global shipping of Beyfortus to prepare healthcare providers months ahead of 2025-2026 RSV season: Paris Tuesday, June 10, 2025, 11:00 Hrs [IST] Sanofi is shipp ...

Meanwhile, Sanofi has pointed to Beyfortus’ 75% reduction in the incidence of MALRI versus Enflosia’s figure of 60%. The ...

Known as Enflonsia, the drug will compete for market share with Sanofi and AstraZeneca’s in-demand Beyfortus, which quickly ...

Merck’s shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus.